Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| APTARGROUP, INC.ATR · Entity 165 | Director | July 16, 2026 | July 17, 2026 |
| Criteo S.A.CRTO · Entity 291 | Chief Financial Officer | August 06, 2026 | August 07, 2026 |
| XPO, Inc.XPO · Entity 3242 | Acting Chief Financial Officer | June 10, 2019 | June 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
APTARGROUP, INC.
Report date July 16, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,553 |
Reported balance
After 2026-07-16 transaction · row 1
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 151 · Balance 4,553 |
Criteo S.A.
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 424,612 |
Reported balance
After 2026-08-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-06 · Sale · Disposed 6,285 · Balance 424,612 F1: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F2: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award.
F2: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission.
XPO, Inc.
Report date June 10, 2019 · Filed June 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 1,951 |
Ending reported balance
After 2019-06-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-06-10 · Exercise / conversion · Acquired 2,842 · Balance 2,842 Row 2 · 2019-06-10 · Tax withholding · Disposed 891 · Balance 1,951 F1: No shares were sold by the Reporting Person. These shares were withheld by the Issuer to fund tax liability attributable to the vesting and settlement of the Restricted Stock Units ("RSUs") reported on this Form 4. These RSUs vested on June 8, 2019, as originally scheduled, and were settled on June 10, 2019, and there were no related discretionary transactions or open market sales. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 14,208 |
Reported balance
After 2019-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-06-10 · Exercise / conversion · Disposed 2,842 · Balance 14,208 F2: Each RSU represents a contingent right to receive, upon settlement, either (i) one share of Common Stock or (ii) a cash payment equal to the fair market value of one share of Common Stock. F3: The RSUs vest in six equal annual installments, beginning on June 8, 2019 and continuing to vest on the next five anniversaries thereof, generally subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: No shares were sold by the Reporting Person. These shares were withheld by the Issuer to fund tax liability attributable to the vesting and settlement of the Restricted Stock Units ("RSUs") reported on this Form 4. These RSUs vested on June 8, 2019, as originally scheduled, and were settled on June 10, 2019, and there were no related discretionary transactions or open market sales.
F2: Each RSU represents a contingent right to receive, upon settlement, either (i) one share of Common Stock or (ii) a cash payment equal to the fair market value of one share of Common Stock.
F3: The RSUs vest in six equal annual installments, beginning on June 8, 2019 and continuing to vest on the next five anniversaries thereof, generally subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
2seventy bio, Inc.
Report date May 13, 2025 · Filed May 15, 2025
Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-13 · Disposition to issuer · Disposed 12,050 · Balance 15,602 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Row 2 · 2025-05-13 · Other · Disposed 15,602 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2025-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-13 · Disposition to issuer · Disposed 24,100 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration.
bluebird bio, Inc.
Report date November 11, 2021 · Filed November 17, 2021
Section 16 reporting ended · disclosed 2021-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-11-11 · Other · Acquired 0 · Balance 0 F1: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on September 29, 2021 and vests vest ratably over three years in annual installments commencing on September 29, 2021. F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-09-29 | Direct | 0 |
Reported balance
After 2021-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-11 · Other · Disposed 7,500 · Balance 0 F4: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on September 29, 2021 and vests ratably over three years in annual installments commencing on September 29, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on September 29, 2021 and vests vest ratably over three years in annual installments commencing on September 29, 2021.
F2: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP").
F3: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP.
F4: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on September 29, 2021 and vests ratably over three years in annual installments commencing on September 29, 2021. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 7, 2026 20:14 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 6,285 | $17.23 | $108,290.55 |
DisclosureSEC source: 0001749338-26-000017 · wk-form4_1786133673.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,612 F1 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F2 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| July 29, 2026 Filed Jul 29, 2026 20:02 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 430,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-050592 · wk-form4_1785355354.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,897 F2 · kind: On July 29, 2026, as previously approved by the Issuer's shareholders, the Issuer completed its conversion (the "Conversion") from a French public limited liability company ("French Criteo") to a Luxembourg public limited liability company ("Lux Criteo"). Upon the Conversion, (i) each Ordinary Share of French Criteo, including shares represented by ADSs, continued as one Ordinary Share of Lux Criteo, (ii) each time-based restricted stock unit and performance-based restricted stock unit of French Criteo continued as a time-based restricted stock unit and performance-based restricted stock unit, respectively, of Lux Criteo and (iii) each option or warrant to obtain shares of French Criteo continued as an option or warrant to obtain an equal number of shares of Lux Criteo, respectively. All rights attached to such awards remain unchanged after the Conversion, except the right to receive shares of French Criteo under these instruments became the right to receive shares of Lux Criteo. F2 · price: On July 29, 2026, as previously approved by the Issuer's shareholders, the Issuer completed its conversion (the "Conversion") from a French public limited liability company ("French Criteo") to a Luxembourg public limited liability company ("Lux Criteo"). Upon the Conversion, (i) each Ordinary Share of French Criteo, including shares represented by ADSs, continued as one Ordinary Share of Lux Criteo, (ii) each time-based restricted stock unit and performance-based restricted stock unit of French Criteo continued as a time-based restricted stock unit and performance-based restricted stock unit, respectively, of Lux Criteo and (iii) each option or warrant to obtain shares of French Criteo continued as an option or warrant to obtain an equal number of shares of Lux Criteo, respectively. All rights attached to such awards remain unchanged after the Conversion, except the right to receive shares of French Criteo under these instruments became the right to receive shares of Lux Criteo. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| July 29, 2026 Filed Jul 29, 2026 20:02 UTC | Criteo S.A. CRTO · Entity 291 | Disposition to issuerOrdinary Shares | 430,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-050592 · wk-form4_1785355354.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Prior to the completion of the Conversion (as defined below), the Ordinary Shares may have been represented by American Depositary Shares ("ADSs"), each of which represents one Ordinary Share and were mandatorily exchanged for one Ordinary Share per each ADS in connection with the Conversion. F2 · kind: On July 29, 2026, as previously approved by the Issuer's shareholders, the Issuer completed its conversion (the "Conversion") from a French public limited liability company ("French Criteo") to a Luxembourg public limited liability company ("Lux Criteo"). Upon the Conversion, (i) each Ordinary Share of French Criteo, including shares represented by ADSs, continued as one Ordinary Share of Lux Criteo, (ii) each time-based restricted stock unit and performance-based restricted stock unit of French Criteo continued as a time-based restricted stock unit and performance-based restricted stock unit, respectively, of Lux Criteo and (iii) each option or warrant to obtain shares of French Criteo continued as an option or warrant to obtain an equal number of shares of Lux Criteo, respectively. All rights attached to such awards remain unchanged after the Conversion, except the right to receive shares of French Criteo under these instruments became the right to receive shares of Lux Criteo. F2 · price: On July 29, 2026, as previously approved by the Issuer's shareholders, the Issuer completed its conversion (the "Conversion") from a French public limited liability company ("French Criteo") to a Luxembourg public limited liability company ("Lux Criteo"). Upon the Conversion, (i) each Ordinary Share of French Criteo, including shares represented by ADSs, continued as one Ordinary Share of Lux Criteo, (ii) each time-based restricted stock unit and performance-based restricted stock unit of French Criteo continued as a time-based restricted stock unit and performance-based restricted stock unit, respectively, of Lux Criteo and (iii) each option or warrant to obtain shares of French Criteo continued as an option or warrant to obtain an equal number of shares of Lux Criteo, respectively. All rights attached to such awards remain unchanged after the Conversion, except the right to receive shares of French Criteo under these instruments became the right to receive shares of Lux Criteo. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 18:35 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 151 | $0.00 | $0.00 |
DisclosureSEC source: 0000896622-26-000150 · form4.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,553 Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:03 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 982 | $18.50 | $18,167.00 |
DisclosureSEC source: 0001749338-26-000015 · wk-form4_1780430579.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,897 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:06 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 1,152 | $17.06 | $19,653.12 |
DisclosureSEC source: 0001749338-26-000013 · wk-form4_1779998803.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,879 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:06 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 1,313 | $17.06 | $22,399.78 |
DisclosureSEC source: 0001749338-26-000013 · wk-form4_1779998803.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 433,031 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| May 06, 2026 Filed May 7, 2026 23:18 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000896622-26-000120 · form4.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,402 Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 20:07 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 83,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001749338-26-000008 · wk-form4_1773691664.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,344 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: The shares are subject to time-based vesting as follows: 25% of the shares will vest on the one (1) year anniversary of the grant date, and the remainder of the shares will vest in equal portions at the end of each quarter over the subsequent thirty-six (36) month period. Notwithstanding the foregoing, if the conversion of the Company into a Luxembourg company is not completed before the first anniversary of the grant date, then the shares will be subject to time based vesting as follows: 50% of the shares will vest on the two (2) year anniversary of the grant date and the remainder of the shares will vest in equal portions at the end of each quarter during the two-year period thereafter. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| March 03, 2026 Filed Mar 3, 2026 21:05 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 1,943 | $18.48 | $35,906.64 |
DisclosureSEC source: 0001749338-26-000006 · wk-form4_1772571946.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,842 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:05 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 18,304 | $17.99 | $329,288.96 |
DisclosureSEC source: 0001749338-26-000006 · wk-form4_1772571946.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,785 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:23 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 4,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001749338-26-000004 · wk-form4_1772486596.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,089 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · shares: On March 1, 2024, the Reporting Person was granted performance-based stock units representing 29,788 shares of the Issuer at the target performance level, with 50% of the units eligible to vest over a two-year performance period and 50% over a three-year performance period. On February 26, 2026, the achievement percentage of the first, two-year performance tranche covering 14,894 shares was determined, resulting in 4,915 shares becoming eligible to time-based vesting on the two year anniversary of the grant date. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:23 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 17,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001749338-26-000004 · wk-form4_1772486596.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,174 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: On February 28, 2025, the Reporting Person was granted performance-based stock units representing 24,343 shares of the Issuer at the target performance level, which would become eligible to vest based on the achievement of performance goals. On February 26, 2026, the achievement percentage was determined, resulting in 17,284 shares becoming eligible to time-based vesting as follows: two thirds of the shares will vest on the two year anniversary of the grant date, and the remainder of the shares will vest on the three year anniversary of the grant date. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| February 24, 2026 Filed Feb 24, 2026 21:15 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 1,541 | $16.71 | $25,750.11 |
DisclosureSEC source: 0001749338-26-000002 · wk-form4_1771967712.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,890 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:15 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 2,796 | $16.81 | $47,000.76 |
DisclosureSEC source: 0001749338-26-000002 · wk-form4_1771967712.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,431 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| November 24, 2025 Filed Nov 24, 2025 21:24 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 3,982 | $19.51 | $77,688.82 |
DisclosureSEC source: 0001749338-25-000005 · wk-form4_1764019465.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,227 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 20:06 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 3,981 | $24.06 | $95,782.86 |
DisclosureSEC source: 0001749338-25-000003 · wk-form4_1756238798.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,209 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| May 27, 2025 Filed May 28, 2025 20:08 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 1,520 | $26.12 | $39,702.40 |
DisclosureSEC source: 0001576427-25-000074 · wk-form4_1748462874.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,190 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| May 23, 2025 Filed May 28, 2025 20:08 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 2,465 | $25.81 | $63,621.65 |
DisclosureSEC source: 0001576427-25-000074 · wk-form4_1748462874.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,710 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:53 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | Disposition to issuerStock Options (Right to buy) · Derivative | 24,100 | Not disclosed Strike: $3.93 | Not disclosed |
DisclosureSEC source: 0001562180-25-003912 · primarydocument.xml · derivative · entry 3 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,100 shares Expires not disclosed F4 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Each Company Option, whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:53 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | OtherCommon Stock | 15,602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003912 · primarydocument.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:53 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | Disposition to issuerCommon Stock | 12,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003912 · primarydocument.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,602 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 10, 2025, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Daybreak Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $5.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of May 13, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Read SEC document |
| May 07, 2025 Filed May 9, 2025 13:28 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 1,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-008959 · form4.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,076 Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:09 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 32,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001576427-25-000033 · wk-form4_1741122542.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,175 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · shares: The shares are subject to time-based vesting as follows: 50% of the shares will vest on the two-year anniversary of the grant date, and the remainder will vest in equal portions at the end of each quarter during the two-year period thereafter. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:09 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 38,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001576427-25-000033 · wk-form4_1741122542.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,719 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: On March 1, 2024, the Reporting Person was granted performance-based stock units representing 59,576 shares of the Issuer at the target performance level, which would become eligible to vest based on the achievement of performance goals. On February 28, 2025, the achievement percentage was determined, resulting in 38,724 shares becoming eligible to time-based vesting as follows: 50% of the shares will vest on the two-year anniversary of the grant date, and the remainder will vest in equal portions at the end of each quarter during a one-year period thereafter. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 21:11 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 17,883 | $40.30 | $720,684.90 |
DisclosureSEC source: 0001576427-25-000025 · wk-form4_1740604290.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,995 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 21:11 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 1,520 | $40.36 | $61,347.20 |
DisclosureSEC source: 0001576427-24-000146 · wk-form4_1732655500.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,878 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| October 23, 2024 Filed Oct 25, 2024 20:13 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 5,442 | $40.60 | $220,945.20 |
DisclosureSEC source: 0001576427-24-000115 · wk-form4_1729887189.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,398 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: The reported amount reflects an adjustment to correct a clerical error in the Reporting Person's Form 4 filed on February 26, 2024, which resulted in the underreporting of the number of performance-based stock units by 158 shares. F4 · balance_after: For more information about the equity of the Issuer held by the Reporting person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| August 26, 2024 Filed Aug 27, 2024 20:11 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 1,519 | $49.17 | $74,689.23 |
DisclosureSEC source: 0001576427-24-000108 · wk-form4_1724789468.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,682 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:17 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 5,496 | $45.49 | $250,013.04 |
DisclosureSEC source: 0001576427-24-000092 · wk-form4_1721938623.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,201 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 18:53 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Options (Right to buy) · Derivative | 24,100 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001562180-24-005008 · primarydocument.xml · derivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,100 Underlying: Common Stock · 24,100 shares Expires 2034-06-10 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 18:53 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 12,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005008 · primarydocument.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,652 F1 · security: These restricted stock units vest 100% on the earlier of June 10, 2025 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| May 24, 2024 Filed May 24, 2024 21:24 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 1,535 | $38.99 | $59,849.65 |
DisclosureSEC source: 0001576427-24-000070 · wk-form4_1716585826.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,697 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| May 01, 2024 Filed May 2, 2024 19:09 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 1,113 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009225 · form4.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,007 Read SEC document |
| April 23, 2024 Filed Apr 23, 2024 20:15 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 5,504 | $35.40 | $194,836.10 |
DisclosureSEC source: 0001576427-24-000043 · wk-form4_1713903318.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,232 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| March 01, 2024 Filed Mar 1, 2024 21:11 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 39,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001576427-24-000022 · wk-form4_1709327485.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,736 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · shares: The shares are subject to time based vesting as follows: 50% of the shares will vest on the two-year anniversary of the grant date, and the remainder will vest in equal portions at the end of each quarter during the two-year period thereafter. F3 · balance_after: For more information about the equity of the issuer held by the reporting person, please see the issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| February 26, 2024 Filed Feb 26, 2024 22:10 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 9,653 | $32.69 | $315,556.57 |
DisclosureSEC source: 0001576427-24-000017 · wk-form4_1708985412.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,019 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F4 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| February 23, 2024 Filed Feb 26, 2024 22:10 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 52,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001576427-24-000017 · wk-form4_1708985412.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,672 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · shares: On February 23, 2023, the Reporting Person was granted performance-based stock units representing 46,600 shares of the Issuer at the target performance level, which would become eligible to vest based on the achievement of performance goals. On February 23, 2024, the achievement percentage was determined, resulting in 52,966 shares becoming eligible to time-based vesting as follows: 50% of the shares will vest on the two-year anniversary of the grant date, and the remainder will vest in equal portions at the end of each quarter during the two-year period thereafter. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 21:20 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 3,622 | $24.74 | $89,608.28 |
DisclosureSEC source: 0001576427-24-000002 · wk-form4_1706131239.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,706 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the reporting person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| October 23, 2023 Filed Oct 25, 2023 20:17 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 2,752 | $28.16 | $77,489.72 |
DisclosureSEC source: 0001576427-23-000123 · wk-form4_1698265070.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,328 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| October 23, 2023 Filed Oct 25, 2023 20:17 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 2,752 | $28.16 | $77,489.72 |
DisclosureSEC source: 0001576427-23-000123 · wk-form4_1698265070.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,080 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| October 17, 2023 Filed Oct 18, 2023 17:35 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 894 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019523 · form4.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894 Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:07 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 2,751 | $32.63 | $89,761.00 |
DisclosureSEC source: 0001576427-23-000098 · wk-form4_1690402044.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,832 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:07 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 2,710 | $32.63 | $88,423.24 |
DisclosureSEC source: 0001576427-23-000098 · wk-form4_1690402044.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,583 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of a previously-reported security award. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 17:02 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantStock Option (right to buy) · Derivative | 16,900 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001562180-23-005220 · primarydocument.xml · derivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,900 Underlying: Common Stock · 16,900 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 13, 2024 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 17:02 UTC | 2seventy bio, Inc. TSVT · Entity 79756 | GrantCommon Stock | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005220 · primarydocument.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,602 F1 · security: These restricted stock units vest 100% on the earlier of June 13, 2024 or the date of the next annual meeting of stockholders of 2seventy bio, Inc. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 20:24 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 2,521 | $30.27 | $76,310.67 |
DisclosureSEC source: 0001576427-23-000052 · wf-form4_168254064519560.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,293 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of previously-reported security awards. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 20:24 UTC | Criteo S.A. CRTO · Entity 291 | SaleOrdinary Shares | 2,521 | $30.27 | $76,310.67 |
DisclosureSEC source: 0001576427-23-000052 · wf-form4_168254064519560.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,814 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · kind: These securities were automatically sold on the Reporting Person's behalf to fund tax withholding obligations arising from the settlement of previously-reported security awards. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:23 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 24,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001576427-23-000029 · wf-form4_167753298949768.xml · nonDerivative · entry 2 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,335 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F4 · shares: On February 24, 2022, the Reporting Person was granted performance-based stock units representing 55,212 shares of the Issuer at the target performance level, which would become eligible to vest based on the achievement of performance goals. On February 23, 2023, the achievement percentage was determined, resulting in 24,661 shares becoming eligible to time-based vesting as follows: 50% of the shares will vest on the two-year anniversary of the grant date, and the remainder will vest in equal portions at the end of each quarter during the two-year period thereafter. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:23 UTC | Criteo S.A. CRTO · Entity 291 | GrantOrdinary Shares | 46,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001576427-23-000029 · wf-form4_167753298949768.xml · nonDerivative · entry 1 Glickman Sarah JS · CIK 0001749338 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,674 F1 · security: The Ordinary Shares may be represented by American Depository Shares, each of which currently represents one Ordinary Share. F2 · shares: The shares are subject to time-based vesting as follows: 50% of the shares will vest on the two-year anniversary of the grant date, and the remainder will vest in equal portions at the end of each quarter during the two-year period thereafter. F3 · balance_after: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission ("SEC"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.